{"id":117272,"date":"2026-01-08T20:36:07","date_gmt":"2026-01-08T20:36:07","guid":{"rendered":"https:\/\/ekamu.net\/?p=117272"},"modified":"2026-01-08T20:36:07","modified_gmt":"2026-01-08T20:36:07","slug":"arastirma-zayiflama-ilaclarini-birakan-kisiler-4-kat-hizli-kilo-aliyor","status":"publish","type":"post","link":"https:\/\/ekamu.net\/index.php\/2026\/01\/08\/arastirma-zayiflama-ilaclarini-birakan-kisiler-4-kat-hizli-kilo-aliyor\/","title":{"rendered":"Ara\u015ft\u0131rma: Zay\u0131flama ila\u00e7lar\u0131n\u0131 b\u0131rakan ki\u015filer 4 kat h\u0131zl\u0131 kilo al\u0131yor"},"content":{"rendered":"

<\/span> Oxford \u00dcniversitesi\u2019nden ara\u015ft\u0131rmac\u0131lar, semaglutid<\/strong> (Wegovy, Ozempic, Rybelsus) ve tirzepatid<\/strong> (Mounjaro) gibi zay\u0131flama ila\u00e7lar\u0131n\u0131 kullanan ki\u015filerin tedavi s\u00fcrecinde kilo verdiklerini, ancak i\u011fneleri b\u0131rakt\u0131ktan sonra yakla\u015f\u0131k 20 ay i\u00e7inde kilolar\u0131n\u0131 geri ald\u0131klar\u0131n\u0131 <\/strong>tespit etti. Bu geri al\u0131m h\u0131z\u0131, yaln\u0131zca diyet yapanlara k\u0131yasla d\u00f6rt kat daha h\u0131zl\u0131<\/strong>. Buna kar\u015f\u0131l\u0131k, sa\u011fl\u0131kl\u0131 beslenme ve egzersizle desteklenen kilo verme programlar\u0131na kat\u0131lan ki\u015filerin verdikleri kiloyu ortalama d\u00f6rt y\u0131l boyunca<\/strong> koruyabildi\u011fi g\u00f6r\u00fcld\u00fc. <\/figure>\n

H\u0131zl\u0131 kilo verdiren ila\u00e7lar b\u0131rak\u0131l\u0131nca kilo al\u0131m\u0131 da h\u0131zlan\u0131yor<\/b><\/p>\n

Oxford \u00dcniversitesi\u2019nden Sam West<\/strong> liderli\u011findeki ara\u015ft\u0131rma ekibi, obezitesi olan 9.341 yeti\u015fkini<\/strong> kapsayan 37 klinik \u00e7al\u0131\u015fmay\u0131<\/strong> inceleyerek tedavi b\u0131rak\u0131ld\u0131ktan sonraki kilo geri al\u0131m\u0131n\u0131 de\u011ferlendirdi. Sonu\u00e7lara g\u00f6re, kilo verme ila\u00e7lar\u0131n\u0131 b\u0131rakanlar ayda ortalama 0,4 kilo<\/strong> al\u0131rken, davran\u0131\u015fsal (diyet\u2013egzersiz) programlar\u0131 b\u0131rakanlarda bu art\u0131\u015f ayda 0,1 kilo<\/strong> ile s\u0131n\u0131rl\u0131 kald\u0131. Daha g\u00fc\u00e7l\u00fc yeni nesil GLP-1<\/strong> ila\u00e7lar\u0131 olan semaglutid <\/strong>ve tirzepatid <\/strong>s\u00f6z konusu oldu\u011funda ise kilo geri al\u0131m\u0131 ayda 0,8 kiloya<\/strong> kadar \u00e7\u0131kt\u0131.<\/p>\n

Her t\u00fcr kilo verme ilac\u0131 kullananlar tedavi s\u0131ras\u0131nda ortalama 8,3 kilo<\/strong> verdi; ancak ilk y\u0131l i\u00e7inde 4,8 kiloyu geri ald\u0131<\/strong> ve ila\u00e7lar b\u0131rak\u0131ld\u0131ktan yakla\u015f\u0131k 1,7 y\u0131l sonra ba\u015flang\u0131\u00e7 a\u011f\u0131rl\u0131klar\u0131na d\u00f6nd\u00fc.<\/strong>\u00a0\u00d6zellikle Wegovy ve Mounjaro<\/strong> kullananlar tedavi s\u00fcrecinde yakla\u015f\u0131k 15 kilo verdi<\/strong>, ancak tedaviyi b\u0131rakt\u0131ktan sonraki ilk y\u0131l i\u00e7inde 10 kilo geri ald\u0131. <\/strong>Ara\u015ft\u0131rman\u0131n projeksiyonlar\u0131na g\u00f6re bu ki\u015filer 1,5 y\u0131l i\u00e7inde<\/strong> t\u00fcm kilolar\u0131n\u0131 yeniden kazan\u0131yor.<\/p>\n

Ayr\u0131ca kan \u015fekeri, kolesterol ve tansiyon gibi kalp-damar ve metabolik g\u00f6stergelerdeki iyile\u015fmelerin de tedavi kesildikten sonra yakla\u015f\u0131k 1,4 y\u0131l<\/strong> i\u00e7inde eski seviyelere d\u00f6nd\u00fc\u011f\u00fc belirtildi.<\/p>\n

Ara\u015ft\u0131rmac\u0131lar ayr\u0131ca, tedavi s\u00fcrecinde verilen davran\u0131\u015fsal deste\u011fin ortalama 4,6 kilo ek kilo kayb\u0131 sa\u011flad\u0131\u011f\u0131n\u0131,<\/strong> ancak ila\u00e7 b\u0131rak\u0131ld\u0131ktan sonraki kilo geri al\u0131m h\u0131z\u0131n\u0131 yava\u015flatmad\u0131\u011f\u0131n\u0131 da not etti.<\/p>\n

West, \u201cBizi en \u00e7ok \u015fa\u015f\u0131rtan \u015fey, ila\u00e7 b\u0131rak\u0131ld\u0131ktan sonra kilonun bu kadar h\u0131zl\u0131 geri gelmesiydi\u201d dedi. Ger\u00e7ek ya\u015fam verileri, obezitesi olan ki\u015filerin yakla\u015f\u0131k %50\u2019sinin GLP-1 ila\u00e7lar\u0131n\u0131 ilk 12 ay i\u00e7inde b\u0131rakt\u0131\u011f\u0131n\u0131 <\/strong>g\u00f6steriyor. Bunun ba\u015fl\u0131ca nedenleri aras\u0131nda y\u00fcksek maliyet<\/strong>, yan etkiler<\/strong> ve eri\u015fim sorunlar\u0131<\/strong> yer al\u0131yor.<\/p>\n

“Obezite kronik ve tekrarlayan bir hastal\u0131k”<\/b><\/p>\n

\u00c7al\u0131\u015fman\u0131n ortak yazarlar\u0131ndan Dr. Susan Jebb, sonu\u00e7lar\u0131n obezitenin kronik ve tekrarlayan<\/strong> bir hastal\u0131k oldu\u011funu net bi\u00e7imde ortaya koydu\u011funu s\u00f6yledi. Jebb, elde edilen faydalar\u0131n korunabilmesi i\u00e7in tedavinin s\u00fcrmesi gerekti\u011fini vurgulayarak, durumu tansiyon ila\u00e7lar\u0131n\u0131n uzun s\u00fcreli kullan\u0131m\u0131na benzetti ve \u00f6m\u00fcr boyu tedavi<\/strong> gerekebilece\u011fini ifade etti.<\/p>\n

Surrey \u00dcniversitesi\u2019nden Dr. Adam Collins ise d\u0131\u015far\u0131dan verilen GLP-1 hormonunun v\u00fccudun kendi hormon \u00fcretimini azaltabilece\u011fini ve duyarl\u0131l\u0131\u011f\u0131 d\u00fc\u015f\u00fcrebilece\u011fini <\/strong>belirtti. Collins\u2019e g\u00f6re, bu \u201cGLP-1 deste\u011fi\u201d kesildi\u011finde i\u015ftah kontrol\u00fc zay\u0131fl\u0131yor ve a\u015f\u0131r\u0131 yeme riski h\u0131zla art\u0131yor.<\/p>\n

\u0130ngiltere\u2019de 2024 ba\u015f\u0131 ile 2025 ba\u015f\u0131 aras\u0131nda yakla\u015f\u0131k 1,6 milyon yeti\u015fkinin<\/strong> kilo vermek amac\u0131yla GLP-1 ila\u00e7lar\u0131 kulland\u0131\u011f\u0131, \u00e7o\u011funun bu ila\u00e7lara \u00f6zel re\u00e7etelerle eri\u015fti\u011fi tahmin ediliyor. ABD\u2019de ise her 8\u00a0yeti\u015fkinden biri<\/strong> hayat\u0131n\u0131n bir d\u00f6neminde GLP-1 ilac\u0131 kullanm\u0131\u015f durumda.<\/p>\n\n

<\/span><\/p>\n

Kaynak :\u00a0https:\/\/www.donanimhaber.com\/zayiflama-ilaclarini-birakan-kisiler-4-kat-hizli-kilo-aliyor–200650<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Oxford \u00dcniversitesi\u2019nden ara\u015ft\u0131rmac\u0131lar, semaglutid (Wegovy, Ozempic, Rybelsus) ve tirzepatid (Mounjaro) gibi zay\u0131flama ila\u00e7lar\u0131n\u0131 kullanan ki\u015filerin tedavi s\u00fcrecinde kilo verdiklerini, ancak i\u011fneleri b\u0131rakt\u0131ktan sonra yakla\u015f\u0131k 20 ay i\u00e7inde …<\/p>\n","protected":false},"author":1,"featured_media":117273,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[7020,4067,7019,975,102],"class_list":["post-117272","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-teknoloji","tag-glp-1","tag-icinde","tag-ilaclar","tag-kilo","tag-tedavi"],"_links":{"self":[{"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/posts\/117272","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/comments?post=117272"}],"version-history":[{"count":1,"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/posts\/117272\/revisions"}],"predecessor-version":[{"id":117275,"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/posts\/117272\/revisions\/117275"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/media\/117273"}],"wp:attachment":[{"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/media?parent=117272"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/categories?post=117272"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/tags?post=117272"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}